ArticlePeerJ2026
Development and validation of a nomogram model for predicting diabetic foot in type 2 diabetes.
Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetic foot (DF) represents a serious complication associated with type 2 diabetes mellitus (T2DM), characterized by elevated rates of morbidity and mortality, alongside substantial healthcare expenditures. Early detection and intervention are essential for enhancing patient prognosis. The objective of this research is to establish a nomogram model for predicting diabetic foot (DF) risk in type 2 diabetes (T2DM). Methods: We conducted a retrospective analysis of 450 individuals with T2DM. Patients were divided into training and validation sets in a 7:3 ratio randomly. We utilized the least absolute shrinkage and selection operator (LASSO) regression, followed by multivariable logistic regression to determine independent risk factors. The performance of the nomogram was evaluated through receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Results: Six independent factors were incorporated into the nomogram: diabetic peripheral neuropathy (DPN), coronary heart disease (CHD), serum albumin (ALB) levels, high-density lipoprotein cholesterol levels (HDLC), fasting blood glucose levels (FBG), and the neutrophil percentage-to-hemoglobin ratio (NPHR). This model demonstrated impressive discrimination, achieving an area under the curve (AUC) of 0.945 (95% confidence interval (CI) [0.9226-0.968]) in the training cohort and 0.941 (95% CI [0.9021-0.9789]) in the validation cohort, while the calibration curves illustrated a positive alignment between predictions and the observed data. Additionally, the DCA revealed clinical benefits. Conclusion: This nomogram enables individualized risk stratification, guiding clinicians to prioritize high-risk patients for preventive care, thereby reducing diabetes-related complications and optimizing resource utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.